Blog

  • Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM

    PHILADELPHIA, PA / ACCESS Newswire / November 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.

    The phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in United States can now expand into additional sites in United Kingdom.

    The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service (NHS) capacity and capability standards.

    “The United Kingdom regulatory and ethical approval is another major step forward in establishing a global footprint of our novel, non-invasive treatment for BCC of the skin, which we believe represents more than $2 billion in potential market opportunity,” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO. “With clinical development programs now active across United States, Europe, and the Middle East, we are enhancing global patient recruitment and clinical dataset which, among other things, would assist us in designing a robust pivotal program”.

    SKNJCT-003 Clinical Trial Design
    The SKNJCT-003 clinical study is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 90 subjects presenting with BCC of the skin. The study evaluates the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.

    The high-dose, 200μg D-MNA, in the study is the maximum dose that was used in the Company’s Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.

    SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC.

    In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

    The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In October 2025, the company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population.

    For further information contact:
    Carolyn Bonner, President and Acting Chief Financial Officer
    (610) 636-0184
    cbonner@medicuspharma.com

    Anna Baran-Djokovic, SVP Investor Relations
    (305) 615-9162
    adjokovic@medicspharma.com

    About Medicus Pharma Ltd.
    Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

    SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

    In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

    In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

    In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients

    In October 2025, the company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population.

    Cautionary Notice on Forward-Looking Statements
    Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SKINJECT™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    SOURCE: Medicus Pharma Ltd

    View the original press release on ACCESS Newswire

  • Survivors of Abuse NJ Outlines Types of Sexual Abuse Cases Handled Across New Jersey

    Survivors of Abuse NJ Outlines Types of Sexual Abuse Cases Handled Across New Jersey

    MT. LAUREL, NJ – November 14, 2025 – PRESSADVANTAGE –

    Survivors of Abuse NJ announced an overview of the types of sexual abuse cases the organization handles throughout New Jersey. Based in Atlantic City, the firm continues to expand public awareness about the scope of sexual abuse litigation and the civil remedies available to survivors under state law. The announcement underscores the organization’s mission to promote transparency, accountability, and access to justice for individuals affected by misconduct in institutional and professional settings.

    “Each sexual abuse case presents unique circumstances, and the civil justice system must address them with fairness and sensitivity,” said Joseph L. Messa, Esq., attorney at Survivors of Abuse NJ. “Our focus remains on helping survivors understand the different forms of abuse that can lead to civil action and the legal processes available to pursue accountability.”

    Atlantic City sexual abuse law firm

    Sexual abuse cases in New Jersey arise in a wide range of contexts involving both individual and institutional defendants. Survivors of Abuse NJ handles cases involving abuse by educators, medical professionals, religious leaders, coaches, and other individuals in positions of authority. These matters frequently include claims against institutions that employed or supervised the accused, based on alleged failures in oversight or reporting. The legal framework governing such cases is complex, requiring detailed evaluation of policies, professional standards, and the actions taken by organizations when allegations were first raised.

    One major category of civil litigation involves abuse in educational institutions. Cases may concern teachers, administrators, or staff who engaged in misconduct or failed to respond appropriately to reports of abuse. Courts review whether school districts met their obligations under state law to protect students, investigate complaints, and implement safeguarding procedures. When these duties are not fulfilled, institutions can face liability for negligence or inadequate supervision.

    Another significant category includes abuse by healthcare professionals. These cases often involve psychiatrists, physicians, therapists, or other licensed practitioners accused of exploiting their professional authority. Civil claims in this area examine whether professional boundaries were violated and whether facilities implemented adequate oversight. The sensitive nature of these cases requires both legal precision and trauma-informed care to ensure survivors’ experiences are treated with respect throughout the process.

    Religious institutions also represent a frequent setting for sexual abuse claims. Many of these cases involve misconduct by clergy members, employees, or volunteers, as well as allegations that organizations failed to investigate or report prior incidents. Civil litigation in this area focuses on institutional accountability and transparency, requiring a review of internal communications, training materials, and response protocols. The aim is not only to secure justice for survivors but also to encourage reforms that prevent future harm.

    Claims arising from sports, youth programs, and community organizations form another core area of Survivors of Abuse NJ’s practice. These cases often involve individuals in supervisory roles, such as coaches or group leaders, whose positions of authority allowed misconduct to occur. The legal process evaluates whether organizations followed background screening procedures, maintained adequate supervision, and enforced appropriate conduct standards. Institutions found to have neglected these duties may be held liable for damages under New Jersey civil law.

    Survivors of Abuse NJ’s work is guided by a trauma-informed approach that emphasizes clarity, confidentiality, and respect for survivors’ autonomy. The firm’s attorneys collaborate with mental health professionals, investigators, and experts to ensure that each case is evaluated comprehensively. By combining legal expertise with awareness of the psychological effects of trauma, the organization strives to make the legal process more accessible and supportive for those affected.

    Legislative developments in New Jersey have broadened the opportunities for survivors to seek justice. The New Jersey Child Victims Act extended the statute of limitations, allowing survivors to file claims until the age of fifty-five or within seven years of recognizing the harm caused by abuse. The act also opened a two-year window for older cases that were previously time-barred. These reforms have prompted renewed efforts to hold institutions accountable for past misconduct and have increased public awareness of survivors’ rights.

    In addition to litigation, Survivors of Abuse NJ engages in public education and outreach to inform communities about the civil legal process. The organization’s materials and seminars explain how claims are filed, what evidence is required, and how institutions can implement stronger preventive measures. These initiatives are designed to ensure that survivors and community members understand the broader social and legal implications of sexual abuse and the steps available to promote systemic change.

    Attorney Joseph L. Messa, Esq., continues to play an active role in advancing survivor advocacy within the civil justice system. His experience in personal injury and institutional misconduct cases informs the firm’s commitment to fairness and integrity in all proceedings. Through continued education, legal representation, and outreach, Survivors of Abuse NJ contributes to statewide efforts to strengthen protections for survivors and to improve accountability within organizations entrusted with care and supervision.

    For more information, visit the Survivors of Abuse NJ website. To learn more about survivor education and legal initiatives, contact Survivors of Abuse NJ directly.

    ###

    For more information about Joseph L. Messa, Esq. – The Abuse Lawyer NJ, contact the company here:

    Joseph L. Messa, Esq. – The Abuse Lawyer NJ
    Joseph L. Messa, Esq.
    (848) 290-7929
    joe@survivorsofabusenj.com
    2000 Academy Dr., Suite 200
    Mt. Laurel, NJ 08054

  • Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

    Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

    Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing

    PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / November 14, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, announced today its financial and operating results for the quarter ending September 30, 2025, and highlighted important corporate updates.

    Third Quarter Corporate Highlights:

    • Skinject Clinical Development Program SKNJCT-003 & SKNJCT-004 Progress:

    The Company is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States. SKNJCT-003, which commenced randomizing patients in August 2024, is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable doxorubicin-containing microneedle arrays (D-MNA).

    In August 2025, the Company announced that SKNJCT-003 has randomized more than seventy-five percent (75%) of the ninety (90) participants expected to be randomized in the study.

    In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of SkinJect, indicating that the Company may follow the FDA’s 505(b)(2) regulatory pathway to non-invasively treat BCC of the skin using dissolvable D-MNA.

    In October 2025, the Company treated its first patient in the clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi is the principal investigator.

    In November 2025, the company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards.

    • Skinject Platform Expansion:

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, to explore co-development of thermostable infectious disease vaccines.

    • Pipeline Expansion-Acquisition of Antev

    In August 2025, the Company completed the acquisition of Antev Limited (“Antev”), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate, a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    • Patient Access & Advocacy-Gorlin Syndrome Alliance Collaboration

    In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable BCCs of the skin to access SkinJect™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect™ in this rare disease population.

    Today the Company also announced its financial and operating results for the quarter ended September 30, 2025, highlights of which are provided below.

    Third Quarter Financial Highlights

    The addition of $10.4 million of aggregate net proceeds from financing transactions and the exercise of warrants has bolstered the Company’s already strong balance sheet as it continues to progress its clinical development program while pursuing strategic acquisition, building out its core management team and strengthening its board of directors.

    Cash and cash equivalents were $8.7 million at the end of the third quarter compared to $5.3 million at the end of the same period in 2024.

    • Total operating expenses were $15.4 million for the third quarter compared to $2.3 million for the same period in 2024.

    • Research and development expenses were $1.7 million for the third quarter compared to $0.6 million for the same period in 2024.

    • General and administrative expenses were $5.0 million for the third quarter compared to $1.8 million for the same period in 2024.

    • Net loss for the third quarter was $16.0 million compared to $2.3 million for the same period in 2024. This reflects increased expenses as the Company accelerates its clinical development program in United States, Europe and the Middle East, raises additional capital, completed the acquisition of Antev in the United Kingdom and continues to integrate Antev into its business and operations, as well as continues to pursue strategic growth.

    The Company’s complete financial statements for the quarter are included in its quarterly report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 14, 2025, and are also available on SEDAR+.

    Management Commentary

    “The fundamentals of the Company continue to remain strong,” stated Dr. Raza Bokhari, Medicus’s Executive Chairman and CEO. “The clinical development program of SkinJect, which we believe represents more the $2 billion in potential market opportunity, is now active across the United States, Europe, and the Middle East. This expansion is enhancing global patient recruitment and our clinical dataset, which, among other things, is expected to assist us in designing a robust pivotal program. Completing the acquisition of Antev has been the highlight of the third quarter, which not only adds strategic depth to our drug development pipeline but also strengthens our team, both at the board and management levels. We believe, Teverelix, a next generation GnRH antagonist, is well positioned to become a first in class product to prevent acute urinary retention relapse due to enlarged prostate, and to treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing approximately US$6 billion in potential market opportunity. The Company’s balance sheet is stable, and management’s confidence level is high.”

    For further information contact:

    Carolyn Bonner, President and Acting Chief Financial Officer
    (610) 636-0184
    cbonner@medicuspharma.com

    Anna Baran-Djokovic, SVP Investor Relations
    (305) 615-9162
    adjokovic@medicuspharma.com

    About Medicus Pharma Ltd.

    Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

    SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate, a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

    In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

    In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

    In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients

    In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect™in this rare disease population.

    In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards

    Cautionary Notice on Forward-Looking Statements

    Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    SOURCE: Medicus Pharma Ltd

    View the original press release on ACCESS Newswire

  • The UniqHouse Roswell Expands Kitchen Remodeling Services Across Metro Atlanta

    The UniqHouse Roswell Expands Kitchen Remodeling Services Across Metro Atlanta

    Roswell, Georgia – November 12, 2025 – PRESSADVANTAGE –

    The UniqHouse Roswell, a full-service home renovation company with over 15 years of experience, announces expanded remodeling services throughout the greater Atlanta metropolitan area, including Alpharetta, Johns Creek, Milton, Sandy Springs, Dunwoody, Woodstock, Marietta, Norcross, Cumming, and Mountain Park. The company specializes in comprehensive kitchen, bathroom, and basement transformations, offering integrated design and construction services from a single provider.

    The expansion comes as homeowners increasingly seek streamlined renovation solutions that eliminate the complexity of coordinating multiple contractors. The UniqHouse Roswell provides complete project management, from initial design consultation through final installation, utilizing in-house craftsmen and dedicated project managers for each renovation.

    Best Kitchen Remodeling Roswell Store

    “Homeowners deserve a renovation experience that transforms not just their spaces, but their entire approach to home improvement,” said a spokesperson for The UniqHouse Roswell. “Our integrated service model means clients work with one team throughout their project, whether they need Kitchen Remodeling Roswell Atlanta services or complete home transformations. This approach significantly reduces the stress and uncertainty that often accompanies major home renovations.”

    The company has earned recognition within the industry, receiving Best of Houzz awards in 2018, 2019, 2020, 2022, and 2023. These accolades reflect the company’s commitment to design excellence and customer satisfaction across all service categories.

    The UniqHouse Roswell offers free design consultations and 3D visualization services, allowing homeowners to preview their renovated spaces before construction begins. This technology-driven approach helps ensure that final results align with client expectations and design preferences. The company’s Cabinet Shop Roswell Atlanta provides custom cabinetry solutions tailored to each project’s specific requirements and aesthetic goals.

    The UniqHouse Roswell maintains partnerships with established kitchen and bath manufacturers throughout the United States, ensuring access to quality materials and innovative design solutions. All work includes a 12-month warranty from the original purchase date, providing additional assurance to homeowners investing in significant renovation projects.

    Beyond kitchen renovations, the company provides comprehensive Bathroom Remodeling Roswell Atlanta services, focusing on creating functional spaces that enhance daily routines. Basement finishing represents another core service area, with the company transforming underutilized spaces into valuable living areas that increase both home functionality and property value.

    The company employs licensed and insured professionals who handle all aspects of the renovation process, including permit acquisition, material selection, and installation. This comprehensive approach distinguishes The UniqHouse Roswell from contractors who may specialize in only one aspect of home renovation.

    The UniqHouse Roswell operates from its showroom location in Roswell, Georgia, where homeowners can view material samples, explore design options, and meet with design consultants. The company has built its reputation on delivering quality craftsmanship at competitive prices while maintaining transparent communication throughout each project phase. With expertise spanning kitchen remodeling, bathroom renovation, basement finishing, and complete home transformations, The UniqHouse Roswell continues to serve residential clients throughout the Atlanta metropolitan area.

    ###

    For more information about The UniqHouse Roswell, contact the company here:

    The UniqHouse Roswell
    The UniqHouse Roswell
    678-218-1993
    contact@theuniqhouse.com
    880 Holcomb Bridge Rd 110 B, Roswell, GA 30076, United States

  • Tamra Bedford, Cosmetic RN Highlights Advanced Microneedling Expertise for Clients

    Tamra Bedford, Cosmetic RN Highlights Advanced Microneedling Expertise for Clients

    San Ramon, California – November 12, 2025 – PRESSADVANTAGE –

    Tamra Bedford, Cosmetic RN, a leading medical spa in San Ramon, emphasizes its specialized expertise in advanced microneedling treatments as demand for non-invasive skin rejuvenation continues to grow throughout the Bay Area. The medical spa, operated by registered nurse Tamra Bedford, focuses on delivering professional-grade collagen induction therapy to address various skin concerns, including fine lines, acne scarring, and uneven skin texture.

    The emphasis on microneedling comes as more clients seek effective alternatives to surgical procedures for skin rejuvenation. Microneedling, also known as collagen induction therapy, uses controlled micro-injuries to stimulate the body’s natural healing response, promoting increased collagen and elastin production. This process results in improved skin texture, reduced appearance of fine lines and wrinkles, and enhanced overall skin tone.

    Tamra Bedford, Cosmetic RN in San Ramon, California

    “Microneedling has become one of our most requested treatments because clients see real, lasting improvements in their skin quality,” said Tamra Bedford, registered nurse and owner of the medical spa. “The technology we use allows us to customize treatment depth and intensity based on each client’s specific skin concerns, whether they’re dealing with acne scarring, enlarged pores, or signs of aging.”

    The medical spa serves clients from throughout the Bay Area who seek professional-grade skincare treatments in a medical setting. As a Cosmetic RN with extensive training in aesthetic procedures, Bedford brings clinical expertise to each treatment, ensuring both safety and optimal results. The spa operates under the medical direction of Dr. Stephen Ronan, MD FACS, as part of Blackhawk Plastic Surgery.

    The growing interest in microneedling San Ramon reflects broader trends in aesthetic medicine toward minimally invasive procedures with minimal downtime. Clients typically experience mild redness immediately following treatment, similar to a mild sunburn, which subsides within 24 to 48 hours. Most clients require a series of treatments spaced four to six weeks apart for optimal results.

    Advanced microneedling treatments at the spa incorporate medical-grade equipment and sterile technique protocols typically found in medical facilities. The procedure can address multiple skin concerns simultaneously, making it an efficient option for clients looking to improve overall skin quality. Treatment areas commonly include the face, neck, décolletage, and hands.

    “What sets medical microneedling apart from at-home devices or non-medical treatments is the depth of penetration we can safely achieve and the sterile environment in which we operate,” added Bedford. “This allows us to deliver more dramatic results while maintaining the highest safety standards.”

    Beyond microneedling, the medical spa offers a comprehensive range of aesthetic services including laser hair removal, Botox and Dysport injections, dermal fillers, chemical peels, and IPL treatments for pigmentation concerns. This full spectrum of services allows the practice to create customized treatment plans that address multiple aesthetic goals.

    Tamra Bedford, Cosmetic RN operates as a physician-supervised medical spa specializing in non-surgical aesthetic treatments. The practice combines medical expertise with advanced technology to deliver safe, effective skincare solutions to clients throughout the San Ramon area and greater Bay Area region.

    ###

    For more information about Tamra Bedford, Cosmetic RN, contact the company here:

    Tamra Bedford, Cosmetic RN
    Tamra Bedford
    hello@tamrabedford.com
    2416 San Ramon Valley Blvd #200, San Ramon, CA 94583

  • MidSolid Press and Pour Expands Contract Manufacturing Capabilities for Solid Shampoo and Conditioner Bars to Serve Growing Business Market

    MidSolid Press and Pour Expands Contract Manufacturing Capabilities for Solid Shampoo and Conditioner Bars to Serve Growing Business Market

    HIGHLANDS RANCH, CO – November 12, 2025 – PRESSADVANTAGE –

    Enhanced production services help American brands capitalize on the booming solid beauty bar industry.

    MidSolid Press and Pour has announced significant enhancements to its contract manufacturing services for solid shampoo and conditioner bars, positioning the company to serve better the rapidly expanding market of American businesses seeking to develop custom hair care products. The improvements come as demand for sustainable, plastic-free beauty alternatives continues to surge across the United States, with Colorado emerging as a key hub for innovative beauty and personal care brands.

    The enhanced manufacturing capabilities specifically target businesses throughout America, with particular focus on Colorado-based companies looking to establish or expand their presence in the solid beauty bar market. These improvements include expanded production capacity, refined formulation processes, and streamlined custom development services designed to help brands bring high-quality products to market more efficiently.

    According to industry reports, the global solid shampoo market has experienced unprecedented growth, driven by consumer demand for environmentally conscious alternatives to traditional liquid hair care products. This trend has created substantial opportunities for businesses to develop their own branded solid shampoo and conditioner lines without the significant capital investment typically required for in-house manufacturing facilities.

    MidSolid Press and Pour’s enhanced services address the key challenges faced by both emerging and established brands. The contract manufacturing approach enables businesses to concentrate on brand development, marketing, and customer relationships, while leveraging specialized manufacturing expertise and established production capabilities. This model proves particularly valuable for Colorado businesses, which often prioritize sustainability and innovation in their product offerings.

    The company’s expanded capabilities include custom formulation development, where experienced chemists work closely with client brands to create unique product formulations tailored to specific market segments or customer needs. This collaborative approach ensures that each brand can differentiate itself in an increasingly competitive marketplace while maintaining the quality standards consumers expect from premium solid hair care products.

    “The solid bar industry represents a fundamental shift in how consumers approach personal care, and we’re seeing tremendous interest from businesses that want to be part of this movement,” said the founder of MidSolid Press and Pour. “Our enhanced manufacturing services remove the barriers that have traditionally prevented smaller brands from entering this market. We’re essentially democratizing access to high-quality solid bar manufacturing, allowing businesses to compete with established players while maintaining their unique brand identity.”

    The enhanced services also include comprehensive quality control measures, packaging solutions, and scalable production options that accommodate businesses at various stages of growth. Whether a Colorado startup seeks to launch its first product line or an established American brand wants to expand into solid hair care products, the manufacturing services can adapt to specific volume requirements and timeline constraints.

    Market research indicates that American consumers increasingly view solid shampoo and conditioner bars as premium alternatives to conventional liquid products. This shift in perception has created opportunities for businesses to command higher profit margins while appealing to environmentally conscious consumers. The solid format eliminates the need for plastic packaging, reduces shipping costs due to concentrated formulations, and offers longer product life compared to liquid alternatives.

    The contract manufacturing model offers particular advantages for businesses operating in competitive markets. By partnering with specialized manufacturers, brands can access advanced formulation expertise, established supplier relationships, and proven production processes without the substantial investment required to develop these capabilities internally. This approach enables businesses to allocate resources toward marketing, brand building, and customer acquisition, rather than investing in manufacturing infrastructure.

    Colorado’s business environment has proven particularly receptive to sustainable beauty innovations, with many local companies leading national trends in environmentally responsible product development. The state’s entrepreneurial culture and commitment to environmental stewardship create an ideal market for solid hair care products, making it a strategic focus area for expanded manufacturing services.

    The enhanced manufacturing capabilities also incorporate advanced testing protocols to ensure product consistency, safety, and performance across all production runs. This attention to quality control helps partner brands build consumer trust and establish strong market positions in an industry where product performance directly impacts brand reputation.

    For businesses considering entry into the solid hair care market, the contract manufacturing approach offers significant risk mitigation compared to independent production efforts. Established manufacturers bring years of experience in ingredient sourcing, formulation optimization, and production efficiency, helping new brands avoid common pitfalls while accelerating their path to market.

    MidSolid Press and Pour’s enhanced services represent a response to growing market demand for accessible, high-quality solid bar manufacturing. As American businesses continue seeking sustainable product alternatives and consumers embrace plastic-free beauty solutions, contract manufacturing services provide the infrastructure necessary for brands to capitalize on these trends while maintaining focus on their core business objectives.

    MidSolid Press and Pour specializes in contract manufacturing of premium solid shampoo and conditioner bars, serving businesses throughout America with custom formulation and production services.

    ###

    For more information about MidSolid Press & Pour, contact the company here:

    MidSolid Press & Pour
    Soap Master Creighton
    (484) 469-7627
    ILove@ColoraradoSoap.com
    362 Mountain Chickadee Rd Highlands Ranch, Colorado 80126

  • Inspire Veterinary Partners Announces Third Quarter 2025 Financial Results

    Inspire Veterinary Partners Announces Third Quarter 2025 Financial Results

    Total revenues increase 7%; net losses decrease 27% compared to prior year period; comparable clinic revenues increase 9.2% vs prior year period

    VIRGINIA BEACH, VA / ACCESS Newswire / November 12, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today reported financial results for the third quarter ended September 30, 2025.

    Third Quarter 2025 Financial Highlights Compared to Prior Periods

    • Total revenue of $4.3 million, a sequential increase of 1% from Q2 2025 and an increase of 7% from the prior year period.

    • Service revenue of $3.13 million, a sequential increase of 1% from Q2 2025 and an increase of 6% from the prior year period.

    • Product revenue of $1.17 million, a sequential increase of 8.2% from Q2 2025 and an increase of 9% from the prior year period.

    • Comparable clinic revenues increased 9.2% from the prior year period.

    • General and Administrative expenses decreased 19% from the prior year period.

    • Net loss of $2.5 million, a decrease of 27% from the prior year period.

    Third Quarter 2025 Operational Highlights

    • Announced launch of online pet pharmacy beginning Q1 2026.

    • Regained compliance with Nasdaq requirement for a minimum of $2.5 million in stockholders’ equity.

    • Presented corporate update at the H.C. Wainwright 27th Annual Global Investment Conference and met with institutional investors.

    Executive Commentary

    “The third quarter of 2025 was a solid quarter of continued progress for IVP and continues our trend of growth compared to the third quarter of 2024 as well as the second quarter of 2025,” said Kimball Carr, Inspire‘s Chairman, President and Chief Executive Officer. “Our team has brought innovative solutions to every aspect of our operations this year and we have celebrated significant clinical hiring that continues to propel our business forward. We continue to control costs and improve efficiency resulting in a 19% decrease in G&A expenses, and we narrowed net losses by 27% from $3.4 million to $2.5 million as compared to last year’s third quarter. After several successive quarters of improved earnings, we are incredibly focused on operations excellence as we continue to grow and move steadily toward profitability.

    “We are also extremely excited about new growth levers and look forward to the Q1 2026 launch of our online pet pharmacy. This planned new business vertical expands our offerings and differentiates our company in the evolving veterinary medicine industry,” concluded Mr. Carr.

    Third Quarter 2025 Financial Overview Compared to Prior Year Period

    • Total revenues for the third quarter of 2025 were $4.3 million, an increase of $267,107 or 7%, compared to $4.0 million for the third quarter of 2024.The year-over-year growth was primarily driven by improved appointment utilization and more consistent veterinarian staffing coverage across core hospitals.

    • Service revenues for the third quarter of 2025 were $3.13 million, an increase of $168,922 or 6%, compared to $2.96 million for the third quarter of 2024. Service revenue increased modestly, supported by higher appointment volume and stronger capture of wellness and preventive care services. The increase in service revenue is mainly attributed to the general increase in spend, specifically per visit spend.

    • Product revenues for the third quarter 2025 were $1.2 million, an increase of $98,000, or 9%, compared to $1.1 million for the third quarter of 2024. Product revenue remained seasonally consistent, reflecting ongoing demand for parasite-prevention and chronic medication refills. Margin performance benefited from strengthened in-clinic pricing discipline and increased pharmacy refill retention through preferred fulfillment channels. The overall increase was a result of customers purchasing more products per visit.

    • General and administrative expenses for the third quarter of 2025 were $2.4 million, a decrease of $564,415 or 19% compared to $2.98 million for the third quarter of 2024. The decrease is primary due to decreased consulting agreements relating to customer outreach and credit card processing fees.

    • Net loss for the third quarter of 2025 was $2.5 million, a decrease of $1 million or 27% compared to $3.5 million for the third quarter of 2024. The reduction of the net loss is primarily attributable to the decline in interest expense and the exclusion of the operating expenses associated with KVC, which was sold during the third quarter of 2024.

    Balance Sheet

    As of September 30, 2025, the Company had cash and cash equivalents of approximately $341,746.

    About Inspire Veterinary Partners, Inc.
    Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.

    Facebook | LinkedIn | X

    Forward-Looking Statements
    This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding plans to launch an online pet pharmacy and management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    Investor Contact
    CORE IR
    516-386-0430
    investors@inspirevet.com

    Press Contact
    CORE PR
    Matthew Cossel
    pr@coreir.com

    General Inquires
    Morgan Wood
    Mwood@inspirevet.com

    Inspire Veterinary Partners, Inc. and Subsidiaries
    Unaudited Condensed Consolidated Balance Sheets

    September 30,

    December 31,

    2025

    2024

    (Unaudited)
    Assets
    Current assets:
    Cash and cash equivalents

    $

    341,746

    $

    523,690
    Accounts receivable, net

    28,704

    40,675
    Inventory

    497,614

    516,650
    Investments – equity securities

    2,571,429

    –
    Prepaid expenses and other current assets

    385,055

    942,456
    Total current assets

    3,824,548

    2,023,471
    Restricted cash – non-current

    234,500

    200,000
    Property and equipment, net

    6,889,958

    6,382,788
    Right-of-use assets

    1,695,171

    1,879,729
    Intangibles assets

    1,175,099

    1,633,927
    Goodwill

    9,088,263

    8,022,082
    Deferred financing costs

    1,000,000

    –
    Other assets

    48,227

    53,997
    Total assets

    $

    23,955,766

    $

    20,195,994
    Liabilities and Stockholder’s Deficit
    Current liabilities:
    Accounts payable

    $

    1,700,265

    1,979,503
    Accrued expenses

    969,940

    285,770
    Operating lease liabilities

    170,774

    183,981
    Loans payable, net of discount

    2,057,740

    2,340,020
    Convertible notes payable

    274,908

    –
    Promissory note

    1,120,623

    –
    Notes payable, net of discount

    3,424,599

    3,410,465
    Total current liabilities

    9,718,849

    8,199,739
    Operating lease liabilities, non-current

    1,813,828

    1,943,487
    Notes payable – noncurrent

    8,254,408

    8,490,763
    Total liabilities

    19,787,085

    18,633,989
    Commitments and Contingencies (Note 15)
    Stockholder’s Equity (Deficit)
    Common stock – Class A, $0.0001 par value, 100 million shares authorized, 3,609,285 and 1,176,059 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    360

    117
    Common stock – Class B, $0.0001 par value, 20 million shares authorized, 3,020,750 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    302

    302
    Preferred stock – Convertible Series B, $0.0001 par value, 10,000 and 0 shares authorized as of September 30, 2025 and December 31, 2024, respectively, and 7,593 and 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    1

    –
    Additional paid in capital

    48,494,176

    37,911,867
    Accumulated deficit

    (44,326,158

    )

    (36,350,281

    )
    Total stockholder’s equity (deficit)

    4,168,681

    1,562,005
    Total liabilities and stockholder’s equity (deficit)

    $

    23,955,766

    $

    20,195,994

    Inspire Veterinary Partners, Inc. and Subsidiaries
    Unaudited Condensed Consolidated Statements of Operations

    For the Three Months Ended
    September 30,

    For the Nine Months Ended
    September 30,

    2025

    2024

    2025

    2024
    Service revenue

    $

    3,138,670

    $

    2,969,748

    $

    9,055,548

    $

    9,735,585
    Product revenue

    1,177,462

    1,079,277

    3,183,327

    3,535,388
    Total revenue

    4,316,132

    4,049,025

    12,238,875

    13,270,973
    Operating expenses
    Cost of service revenue (exclusive of depreciation and amortization, shown separately below)

    2,678,940

    2,568,085

    7,253,536

    7,705,972
    Cost of product revenue (exclusive of depreciation and amortization, shown separately below)

    850,153

    854,921

    2,507,227

    2,807,025
    General and administrative expenses

    2,423,707

    2,988,122

    7,514,420

    8,080,199
    Debt extinguishment loss

    –

    –

    689,411

    1,587,862
    Depreciation and amortization

    330,498

    340,167

    864,293

    1,048,290
    Gain on sale of business

    –

    (467,049

    )

    –

    (467,049

    )
    Total operating expenses

    6,283,298

    6,284,246

    18,828,887

    20,762,299
    Loss from operations

    (1,967,166

    )

    (2,235,221

    )

    (6,590,012

    )

    (7,491,326

    )
    Other income (expenses):
    Interest income

    4

    44

    25

    46
    Interest expense

    (559,111

    )

    (1,254,149

    )

    (1,385,891

    )

    (2,801,491

    )
    Other income (expenses)

    –

    –

    –

    (4,768

    )
    Total other expenses

    (559,108

    )

    (1,254,105

    )

    (1,3785,866

    )

    (2,806,213

    )
    Loss before income taxes

    (2,526,273

    )

    (3,489,326

    )

    (7,975,878

    )

    (10,297,539

    )
    Benefit for income taxes

    –

    –

    –

    –
    Net loss

    (2,526,273

    )

    (3,489,326

    )

    (7,975,878

    )

    (10,297,539

    )
    Dividend on convertible series A preferred stock

    –

    –

    –

    (220,850

    )
    Net loss attributable to class A and B common stockholders

    $

    (2,526,273

    )

    $

    (3,489,326

    )

    $

    (7,975,878

    )

    $

    (10,518,389

    )
    Net loss per Class A and B common shares:
    Basic and diluted

    $

    (0.41

    )

    $

    (0.85

    )

    $

    (1.55

    )

    $

    (2.64

    )
    Weighted average shares outstanding per Class A and B common shares:
    Basic and diluted

    6,091,057

    4,112,531

    5,154,703

    3,989,3443

    SOURCE: INSPIRE VETERINARY PARTNERS, INC.

    View the original press release on ACCESS Newswire

  • RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

    RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

    ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion.

    RedChip began introducing Cidara to its global microcap and small-cap investor network in 2021, when the company’s market capitalization was under $100 million and its groundbreaking antiviral and antifungal programs were still largely undiscovered by the broader investment community.

    “Cidara’s journey from a sub-$100 million emerging growth story to a multibillion-dollar strategic acquisition by Merck is exactly the type of transformational outcome RedChip seeks to spotlight for investors,” said Dave Gentry, CEO of RedChip Companies. “We were proud to share the Cidara story at a time when its innovative Cloudbreak® platform and long-acting antiviral programs were just beginning to attract institutional attention. Seeing that early science culminate in one of the largest biotech acquisitions of the year validates both Cidara’s vision and the importance of bringing promising small-cap opportunities to investors early.”

    As detailed in Merck’s announcement, the acquisition centers on CD388, Cidara’s investigational long-acting, strain-agnostic antiviral designed to prevent influenza infection in individuals at high risk of complications. CD388, now in Phase 3 development, was granted Breakthrough Therapy Designation by the FDA and is viewed as a potentially first-in-class seasonal prevention solution with global commercial potential.

    “Cidara exemplifies the type of emerging blue-chip story that aligns with RedChip’s 33-year mission,” Gentry added. “We congratulate the Cidara team on this extraordinary milestone and look forward to continuing our work discovering tomorrow’s leading innovators today.”

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

    To learn more about RedChip’s products and services, please visit: https://www.redchip.com/corporate/investor_relations

    “Discovering Tomorrow’s Blue Chips Today”™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-REDCHIP (733-2447)
    1-407-644-4256
    info@redchip.com

    –END–

    SOURCE: RedChip Companies, Inc.

    View the original press release on ACCESS Newswire

  • Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States

    Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States

    NEW YORK, Nov. 14, 2025 / PRZen / Outreaching.io announced today that Rameez Ghayas Usmani has been appointed as the company’s Chief Executive Officer. According to the board of directors, the appointment reflects Rameez’s professional experience in digital PR and SEO, as well as his recognition as the Best HARO Link Building Expert in the United States by BestofBestReview.com

    Rameez has extensive experience with HARO (Help A Reporter Out) and Qwoted outreach, connecting organizations with journalists to secure editorial backlinks from reputable publications. His work includes structured campaigns across multiple sectors aimed at delivering consistent, measurable media placements and strengthening professional outreach practices.

    In his new role, Rameez will oversee strategic operations at Outreaching.io and guide initiatives in digital PR and SEO. The board emphasized that the appointment aligns with the company’s plans to reinforce executive leadership and operational continuity as it continues to grow.

    Rameez has worked with clients across technology, finance, healthcare, and e-commerce, focusing on editorially earned placements. The board stated that his experience supports Outreaching.io’s commitment to ethical outreach and professional standards in link-building strategies.

    “This appointment reflects the board’s confidence in Rameez’s professional expertise,” said a spokesperson for Outreaching.io. “His recognition as the Best HARO Link Building Expert in the United States highlights his understanding of industry practices and the company’s dedication to structured, ethical media outreach.”

    As CEO, Rameez will implement systems to support consistent outreach practices, including tools for media opportunity tracking and reporting. These initiatives are intended to maintain professional standards in HARO link building and support reliable service delivery to clients.

    The board noted that Rameez will also contribute to policy development and staff guidance, ensuring high-quality outreach services across all client accounts. His leadership is expected to reinforce Outreaching.io’s focus on ethical, results-oriented digital PR and link-building practices.

    Under Rameez’s direction, Outreaching.io is targeting faster turnaround times for client campaigns, higher placement rates in Tier-1 publications, and measurable growth in clients’ inbound leads from earned media including New York Times, Forbes, Business Insider, and more. Recognized as the Best HARO Link Building Expert, Rameez is implementing systems to optimize the company’s HARO pipeline—shortening response cycles and improving journalist-brand match accuracy.

    The board stated that these operational goals are intended to strengthen client ROI and reinforce Outreaching.io’s position as a leader in credible, performance-driven HARO link building.

    About Outreaching.io

    Outreaching.io is a link-building and digital PR agency. The agency provides journalist outreach and HARO link-building services to clients across multiple industries. Its approach emphasizes authentic relationships with media professionals and measurable results in organic visibility and authority.

    Media Contact
    Outreaching.io – Rameez Ghayas Usmani
    +971585709698
    rameez@outreaching.io

    Press Release Distributed by PRLog

    Source: Outreaching.io

    Follow the full story here: https://przen.com/pr/33598505

  • Araptus launches affordable Black Friday web package for small businesses at $900 setup + $100/month

    Araptus launches affordable Black Friday web package for small businesses at $900 setup + $100/month

    “Small Business Focus: Professional Results Without Breaking the Bank”

    Houston, TX – November 15, 2025 – Araptus announces a limited-time Black Friday offer for small businesses: a professional website package at just $900 setup and $100/month with a 1-year agreement. Designed for local businesses and startups, this deal eliminates the typical $5,000–$15,000 cost of traditional agencies. The promotion runs through November 30, 2025, with bonus support for early adopters.

    The Araptus Small Business Package addresses a critical gap in the market: most small businesses face a difficult choice between expensive custom development ($8,000-$15,000+) or limited DIY website builders that hurt SEO and performance. Araptus bridges this gap by providing professional-quality websites built on modern technology (Astro.js) that deliver 90+ PageSpeed scores, strong SEO optimization, and all the essential features small businesses need to compete online. Unlike template-based builders that slow down over time, Araptus sites are engineered for performance from day one, helping businesses get found on Google and convert visitors into customers.

    Everything Small Businesses Need to Succeed Online

    The Small Business Package includes all the essential features businesses need to establish a professional online presence:

    Professional SEO-optimized pages – Each page is built with search engine optimization best practices, helping businesses rank on Google and get found by local customers.

    Contact form with email integration – Capture leads directly through the website with instant email notifications for every inquiry.

    Booking calendar integration – Schedule appointments, consultations, or services directly through the website with integrated calendar functionality.

    Blog system with CMS – Publish articles, news, and updates easily through an integrated content management system, perfect for content marketing.

    Mobile-responsive design – Websites look great and function perfectly on all devices, from smartphones to desktop computers.

    SSL security & GDPR compliance – Built-in security features and privacy compliance protect both the business and its customers.

    Google Analytics 4 integration – Track website visitors, understand customer behavior, and make data-driven business decisions.

    FAQ & testimonials sections – Build trust and answer common questions with pre-built sections for social proof and customer support.

    Cookie consent system – GDPR-compliant cookie consent management is included to meet privacy regulations.

    Privacy policy & legal pages – Essential legal pages are set up to protect the business and comply with regulations.

    Managed hosting & updates – The $100/month fee covers hosting, security updates, and ongoing technical maintenance, so business owners can focus on their business instead of website management.

    The package provides everything needed for a small business to have a professional, fast, and secure website without requiring technical expertise.

    Quick Launch, Transparent Pricing, and Black Friday Bonuses

    Speed is a major advantage: Araptus delivers completed websites in just 1-2 weeks, allowing businesses to get online quickly during the critical holiday season and into 2026. The pricing structure is straightforward with no hidden fees: $900 covers the complete website setup and launch, while $100 per month covers hosting, security updates, backups, and ongoing support under a 1-year minimum service agreement.

    Black Friday Exclusive Bonuses:

    • Extended 60-day support period (versus standard 30 days)
    • Priority email support queue for faster response times
    • Free video training session to master website management
    • Content remains accessible to clients with export capabilities at any time

    After the initial year, the service continues month-to-month with 30 days written notice required to discontinue. Clients maintain access to all their content and data, which can be exported per the service agreement terms. This transparent approach ensures businesses know exactly what they’re getting and what they’re paying for, with no surprise fees or long-term obligations beyond the first year.

    Founder’s Vision: Professional Quality for Small Business Budgets

    “Small businesses are the backbone of our economy, but they often face impossible choices when it comes to websites,” said Kris Black, Founder of Araptus. “Pay $8,000-$15,000 upfront to an agency, or settle for a slow DIY builder that hurts your Google rankings. Neither option is good. Our Small Business Package offers a third way: professional quality at a price point that actually works for small businesses. For $900 to launch and $100 a month, you get a website that performs like it cost $10,000+, but without destroying your startup budget.”

    Kris Black, an experienced software engineer, built Araptus after seeing too many small businesses struggle with overpriced, underperforming websites. “The technology exists to build lightning-fast, SEO-optimized websites efficiently. We’re using modern frameworks like Astro.js to deliver 90+ PageSpeed scores and professional features without the traditional enterprise price tag. This Black Friday promotion lets us prove that small businesses deserve better than templates and can afford better than typical agency rates.”

    Limited-Time Black Friday Offer with Cyber Monday Extension

    This Black Friday offer runs through November 30, 2025, with the same pricing and bonuses extending through Cyber Monday (December 2, 2025) for those who miss the Black Friday deadline. The exclusive bonuses—extended 60-day support, priority email assistance, and free video training—are only available during this promotional period and will not be offered again until next year.

    Small business owners planning launches or website upgrades for 2026 should act quickly to lock in this pricing. Enterprise upgrade options are also available for businesses needing advanced features: the Starter Upgrade ($2,500) adds interactive quizzes and location-based landing pages, while the E-Commerce package (starting at $5,000) includes full Shopify or WooCommerce integration with product catalogs and checkout systems.

    Interested business owners can learn more and secure their spot at the Araptus Black Friday page: https://araptus.com/black-friday or the Cyber Monday page: https://araptus.com/cyber-monday. This is an opportunity to start 2026 with a professional website that drives real business results, without the typical five-figure price tag.

    About Araptus

    Araptus is a Houston-based web development company specializing in high-performance websites for small businesses and startups. Built on modern web technology (Astro.js), Araptus websites consistently achieve 90+ PageSpeed scores and are optimized for search engine visibility from day one. The company serves local businesses, solopreneurs, and growing companies who need professional web presence without enterprise budgets. Araptus maintains and hosts client websites through transparent month-to-month service agreements, with clients retaining access to their content and data. For more information, visit Araptus.com.

    Media Contact
    Company Name: Araptus
    Contact Person: Kris Black
    Email: Send Email
    Address:Houston, TX
    Country: United States
    Website: https://araptus.com/black-friday

     

    Press Release Distributed by ABNewswire.com

    To view the original version on ABNewswire visit: Araptus launches affordable Black Friday web package for small businesses at $900 setup + $100/month